Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.30 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29960741 | 0.72 | HTR2C (0.43) | HTR2C | |
| SCHEMBL29960392 | 0.59 | PARP10 (0.36) | PARP1PARP10PARP11HTR2C | |
| SCHEMBL2275422 | 0.58 | HTR2A (0.50) | PARP1PARP10PDPK1PARP11HTR2C | |
| SCHEMBL17457429 | 0.56 | GID4 (0.44) | PARP1PARP10PDPK1PARP11HTR2C | |
| SCHEMBL12714991 | 0.56 | PARP10 (0.54) | PARP1PARP10PDPK1PARP11HTR2C | |
| SCHEMBL7772712 | 0.55 | PRCP (0.42) | PARP1PARP10PDPK1PARP11HTR2C | |
| SCHEMBL8367481 | 0.55 | HTR2A (0.43) | PARP1PARP10PDPK1PARP11HTR2C | |
| SCHEMBL14178994 | 0.55 | PDPK1 (0.45) | PARP1PARP10PDPK1PARP11HTR2C | |
| SCHEMBL4127623 | 0.55 | ANPEP (0.50) | PARP1PARP10PDPK1PARP11HTR2C | |
| SCHEMBL4117416 | 0.55 | ANPEP (0.50) | PARP1PARP10PDPK1PARP11HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022204150-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CNS DISORDERS | BLUE OAK PHARMACEUTICALS, INC. (US) | 2022-09-29 | — | — | WO | disclosed |